Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).

Annals of hematology ·Vol. 83 Suppl 1 ·2004-00-00 ·Pages S65-6

Hochhaus A

Abstract

暂无摘要

MeSH Terms

Antineoplastic Agents/adverse effects,therapeutic use Benzamides Chromosome Aberrations/chemically induced Clinical Trials as Topic Gastrointestinal Neoplasms/drug therapy,genetics Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy,genetics Piperazines/adverse effects,therapeutic use Pyrimidines/adverse effects,therapeutic use Stromal Cells/drug effects,pathology

Chemicals

Antineoplastic Agents Benzamides Piperazines Pyrimidines Imatinib Mesylate

Authors & Affiliations

1 authors, click to expand affiliations / ORCID

Hochhaus A

III. Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany.

Article Info

Journal

Annals of hematology

Abbr.

Ann Hematol

ISSN

0939-5555

DOI

10.1007/s00277-004-0850-2

Published

2004-00-00

Pages

S65-6

Language

English

Region

Germany

NLM ID

9107334

Subset

External Links

PubMed source DOI: 10.1007/s00277-004-0850-2 View journal details

Analysis Services

Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).

Contact

WeChat Official Account